Cogent Biosciences, Inc. COGT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$354.3M-31.5% | -$328.94M-28.6% | -$294.37M-21.5% | -$284.08M-25.1% | -$269.5M-27.0% | ||
| $2.55M+2.4% | $2.56M+4.7% | $2.56M+5.7% | $2.54M+6.5% | $2.49M+6.5% | ||
| $52.98M+31.3% | $46.08M+16.0% | $40.31M+4.4% | $40.06M+8.2% | $40.36M+18.1% | ||
| $879K— | $601K— | $363K— | $63K— | $0— | ||
| —— | —— | —— | —— | $0+100% | ||
| -$410K— | -$2.51M— | —— | —— | —— | ||
| $9.14M-34.8% | $10.69M-33.0% | $7.25M-43.9% | $9.6M-21.7% | $14.02M+250% | ||
| $4.2M— | $195K— | $345K— | —— | —— | ||
| $57K+1,040% | $33K— | $20K— | $9K— | $5K— | ||
| $2.05M+6.1% | $2.02M+6.2% | $1.99M+23.2% | $1.96M+38.9% | $1.93M+21.4% | ||
| —— | -$7.18M— | -$5.39M— | -$3.59M— | -$1.8M— | ||
| -$284.82M-28.4% | -$264.44M-27.3% | -$245.92M-28.6% | -$233.61M-31.8% | -$221.77M-33.1% | ||
| $1.46M+38.7% | $1.55M+171% | $818K+0.6% | $1.03M+58.0% | $1.05M-40.4% | ||
| -$505.36M-574% | -$399.53M-1,144% | -$15.09M— | $200.15M— | $106.61M— | ||
| —— | $54.64M— | $40.98M— | $27.32M— | $13.66M— | ||
| $17.17M+12,522% | $11.55M— | $1.19M— | $141K— | $136K— | ||
| —— | $48.9M— | $36.67M— | $24.45M— | $12.22M— | ||
| $905.8M+3,436% | $878.23M+309% | $289.59M+34.9% | $72.85M-66.1% | $25.62M-93.2% | ||
| $117.59M— | $216.23M— | $30.55M— | $39.38M— | —— | ||
| —— | —— | —— | —— | $7.18M— | ||
| $879K— | $601K— | $363K— | $63K— | $0— | ||
| —— | $2.56M+4.7% | $2.54M+5.4% | $2.51M+6.2% | $2.48M+7.1% | ||
| $9.14M-34.8% | $10.69M-33.0% | $7.25M-43.9% | $9.6M-21.7% | $14.02M+250% | ||
| -$1.61M-12.5% | -$1.57M-12.9% | -$1.52M-13.1% | -$1.48M-25.3% | -$1.43M-52.5% | ||
| -$2.92M— | -$1.56M— | -$378K— | —— | —— | ||
| $4.2M— | $195K— | $345K— | —— | —— | ||
| $2.05M+6.1% | $2.02M+6.2% | $1.99M+23.2% | $1.96M+38.9% | $1.93M+21.4% | ||
| —— | $223.1M— | $167.33M— | $111.55M— | $55.78M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $24.25M— | ||
| —— | $54.64M— | $40.98M— | $27.32M— | $13.66M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $79K— | ||
| -$286.27M-28.5% | -$266M-27.7% | -$246.73M-28.4% | -$234.65M-31.9% | -$222.82M-32.3% | ||
| -$286.27M-28.5% | -$266M-27.7% | -$246.73M-28.4% | -$234.65M-31.9% | -$222.82M-32.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cogent Biosciences, Inc. generate?
- Cogent Biosciences, Inc. (COGT) generated -$284.8M in operating cash flow over the trailing twelve months.
- What is Cogent Biosciences, Inc.'s free cash flow?
- After $1.5M of capital expenditures, Cogent Biosciences, Inc.'s free cash flow was -$286.3M over the trailing twelve months, down 28.5% year over year.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
